` REPL (Replimune Group Inc) vs S&P 500 Comparison - Alpha Spread

REPL
vs
S&P 500

Over the past 12 months, REPL has outperformed S&P 500, delivering a return of 12% compared to the S&P 500's 9% growth.

Stocks Performance
REPL vs S&P 500

Loading
REPL
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
REPL vs S&P 500

Loading
REPL
S&P 500
Difference
www.alphaspread.com

Performance By Year
REPL vs S&P 500

Loading
REPL
S&P 500
Add Stock

Competitors Performance
Replimune Group Inc vs Peers

S&P 500
REPL
ABBV
AMGN
GILD
VRTX
Add Stock

Replimune Group Inc
Glance View

Market Cap
731.5m USD
Industry
Biotechnology

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-07-20. The firm is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The firm applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The firm is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The firm is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.

REPL Intrinsic Value
Not Available
Back to Top